1346508-30-2

Upstream product

• 863036-64-0 (2E)-3-(2-thienyl)-N-(1-hydroxy-2,2,2-trichloroethyl)acrylamide 
• 1346508-40-4 (2E)-3-(2-thienyl)-N-(1-isothiocyano-2,2,2-trichloroethyl)acrylamide 
• 134-20-3 2-carbomethoxyaniline 
• 1124-65-8 3-(2-thienyl)-2-propenoic acid 

Relevant academic research and scientific papers

ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS

The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof; the present invention also relates to a composition comprising a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; especially use for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

SAR, cardiac myocytes protection activity and 3D-QSAR studies of salubrinal and its potent derivatives

Salubrinal is a selective inhibitor of endoplasmic reticulum (ER) stress and affords remarkable protection to cardiomyocytes. By studying the structure-activity relationship (SAR) of salubrinal, it was found that modification of the quinoline ring terminus and thiourea unit could confer the compound PP1-24 with markedly enhanced cardioprotective activity (EC 50 2 = 0.741, r2 = 0.991).